Compare XENE & NUVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | XENE | NUVB |
|---|---|---|
| Founded | 1996 | 2018 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.4B | 2.9B |
| IPO Year | 2014 | N/A |
| Metric | XENE | NUVB |
|---|---|---|
| Price | $42.43 | $8.82 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 11 | 8 |
| Target Price | ★ $53.91 | $10.63 |
| AVG Volume (30 Days) | 857.1K | ★ 5.7M |
| Earning Date | 02-26-2026 | 11-03-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $7,500,000.00 | ★ $26,748,000.00 |
| Revenue This Year | N/A | $609.55 |
| Revenue Next Year | N/A | $197.91 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 1137.19 |
| 52 Week Low | $26.74 | $1.54 |
| 52 Week High | $46.60 | $9.75 |
| Indicator | XENE | NUVB |
|---|---|---|
| Relative Strength Index (RSI) | 44.90 | 58.19 |
| Support Level | $40.41 | $8.04 |
| Resistance Level | $46.36 | $9.12 |
| Average True Range (ATR) | 1.59 | 0.45 |
| MACD | -0.43 | -0.18 |
| Stochastic Oscillator | 30.35 | 47.52 |
Xenon Pharmaceuticals Inc is a neuroscience-focused biopharmaceutical company committed to improving the lives of people living with neurological and psychiatric disorders. It is advancing a novel product pipeline to address areas of high unmet medical need, including epilepsy and depression. The product candidates of the group include XEN1101, NBI-921352, and XEN496 for Epilepsy and Nav1.7 oral inhibitors for Pain.
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor specifically designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes differentiated, novel oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in their different stages of development. The company generates revenue through out-licensing collaborative agreements with its customers located in China and Japan.